IPSEN’S STRENGTHS ARE DEEPLY DISCOUNTED BY MARKETS (BUY; 53% UPSIDE)
30/04/24 -" Similar to other Smaller Pharmas, the family-controlled Ipsen’s (BUY; France) share price performance over the last two years has been disappointing (also underperforming the broader markets). From ..."
Pages
54
Language
English
Published on
30/04/24
You may also be interested by these reports :
21/05/24
Jean-Paul Clozel to step down as CEO
20/05/24
BioNTech (Buy, Germany) is a beacon among the much-battered German biotechnology cohort. Founded with venture capital in 2008, the company sits on a ...
17/05/24
We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of ...
15/05/24
The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless ...